Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

• Status: Completed
• Trial end date: 2003-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bupropion

Criteria

Inclusion criteria:

• Patient must be diagnosed with ADHD.

Exclusion Criteria:

• Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.

• Patient has a current diagnosis of Major Depressive Disorder (MDD).

• Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.

• Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.

• Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.